<DOC>
	<DOCNO>NCT02767401</DOCNO>
	<brief_summary>The purpose study investigate effect percutaneous coronary intervention ( PCI ) myocardial viability coronary artery disease patient single coronary total occlusion ( CTO ) lesion .</brief_summary>
	<brief_title>The Success Opening Single CTO Lesions Improve Myocardial Viability Study ( SOS-comedy )</brief_title>
	<detailed_description>Patients coronary artery disease might benefit successful percutaneous coronary intervention ( PCI ) . However , currently consensus optimal treatment modality single lesion result coronary total occlusion ( CTO ) . Since coronary artery often lesion-free , stenosis le 50 % , patient often present symptom . Although expert consensus CTO lesion suggest reduce incidence long-term adverse event via successful revascularization , retrospective study single CTO lesion . To date , unclear whether successful PCI base optimal medication treatment ( OMT ) increase myocardial viability extent myocardial viability relate prognosis CTO patient . Therefore , aim multi-center , prospective , open label , non-randomized control study determine improvement myocardial viability single CTO patient successful PCI plus OMT superior patient OMT .</detailed_description>
	<mesh_term>Myocardial Stunning</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<mesh_term>Calcium Channel Blockers</mesh_term>
	<criteria>History stable unstable angina LVEF &gt; 35 % transthoracic echocardiography measurement Single lesion occlude coronary artery detect angiography MSCTA , without stenosis coronary artery ( ≤ 50 % stenotic lesion ) Availability followup 12 month No major barrier provide write consent Acute Qwave myocardial infarction late 3 month Revascularization nonculprit artery late one month Unsuitable PCI Unable tolerate dual antiplatelet treatment ( DAPT ) Severe abnormal hematopoietic system , platelet count &lt; 100×109/L &gt; 700×109/L white blood cell count &lt; 3×109/L Active bleed bleeding tendency Severe coexisting condition , severe renal insufficiency ( GFR &lt; 60 ml/min•1.73m2 ) , severe hepatic dysfunction [ elevate ALT ( glutamicpyruvic transaminase ) AST ( glutamicoxal acetic transaminase ) level threefold normal limitation ] , acute chronic heart failure ( NYHA IIIIV ) , acute infectious disease , immune disorder , malignancy , etc . Life expectancy &lt; 12 month Pregnancy plan pregnancy Drug allergy contraindication aspirin , clopidogrel , ticagrelor , statin , contract , anticoagulant , stent , etc . Participation plan participate another clinical trial period Refusal comply study protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>PET-CT</keyword>
	<keyword>Cardiac magnetic resonance ( CMR ) imaging</keyword>
	<keyword>Major adverse cardiac event ( MACEs )</keyword>
	<keyword>coronary artery disease</keyword>
</DOC>